The National Institute of Allergy and Infectious Disease (NIAID) shared a study of remdesivir, a drug developed by Gilead Sciences Inc. and NIAID-supported investigators which involved six rhesus macaques. One group of monkeys received remdesivir and the other animals served as an untreated comparison group. Scientists infected both groups with SARS-CoV-2. Twelve hours later the treatment group received a dose …